Ms. Seroogy joined DiCE Molecules in August 2018 as Senior Director of clinical pharmacology and DMPK where she is responsible for lead selection and optimization of compounds from research through early development. Prior to DiCE Molecules, Ms. Seroogy was at Achaogen for 6 years contributing to the DMPK and clinical pharmacology functions which advanced ZEMDRI™ (plazomicin), a gram-positive antibiotic, and its complementary diagnostic immunoassay through clinical trials and FDA approval.
Ms. Seroogy spent 6 years as a Director of Research at PharmacoFore heading the analytical, bioanalytical and DMPK functions in the field of pain and anesthesia. The team advanced 5 programs from discovery into development with multiple programs successfully completing human Phase 1 clinical studies. Ms. Seroogy spent 8 years at Theravance. where she contributed to progressing VIBATIV® (telavancin), a gram-negative antibiotic, from discovery through Phase 3 clinical development. Prior to Theravance, Ms. Seroogy was in the bioanalytical and pharmacokinetic department at COR Therapeutics where she focused on cardiovascular drugs and contributed to the development of INTEGRILIN® (eptifibatide). Ms. Seroogy holds a B.S. in Zoology from Arizona State University.